🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

0.03 mL Serving Size
40 Servings
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

30 mcg (25% DV)
✅ Within RDA (0.2× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.03mg
15 mcg (50% DV)
✅ Within RDA (0.1× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.015mg
5 mcg (200% DV)
📊 Market median: 0.1mg (347 products) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.005mg

Other Ingredients

Medium Chain Triglyceride Oil Mixed Berry Flavor, Natural

Label Claims — Verification

Nutrient
All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Children 4 or More Years of Age Organic Infants/Baby (0 - 1 Year) Children more than 1 but less than 4

Product Information

📋 Directions for Use

Suggested Use: Infants 0 - 12 mos: 1 drop every other day Children 1-3 yrs: 3 drops daily Children 4+ yrs: 6 drops daily

⚠️ Warnings & Precautions

Contains coconut.

🧪 Formulation Notes

Certified Organic by Oregon Tilth: Oregon Tilth Certified Organic (OTCO) USDA Organic

Vitamin K2 Drops 5 mcg per drop

Additional Information

Store in a cool dry place.

Oregon Tilth Certified Organic (OTCO) USDA Organic

Product Details

DSLD Entry Date 2025-05-21
Product Type Vitamin
Form Liquid
DSLD ID 327009
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →